There are currently 1471 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT06026332
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Ferring Investigation Site, Dallas, Texas
Conditions: Bladder Cancer
Register for Updates
NARCOMS Registry: a Multiple Sclerosis Registry
NCT01018537
Recruiting
This project is based on the idea that we can learn about the complexities of MS by following disease and treatment patterns in a large group of people over several years. The information gathered is used for research only. Results are presented in summary form only. All details submitted by registry participants is strictly confidential. To participate in NARCOMS complete the baseline enrollment survey online through www.narcoms.org (or directly using the following link: https://redcap.link/py... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Multiple Sclerosis
Register for Updates
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
NCT05112237
Recruiting
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
11/11/2024
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: Cardiomyopathy
Register for Updates
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT06136884
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer
Register for Updates
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/11/2024
Locations: MBX Biosciences Investigational Site, Dallas, Texas
Conditions: Hypoparathyroidism
Register for Updates
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051
Recruiting
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: GSK Investigational Site, Dallas, Texas
Conditions: Neoplasms
Register for Updates
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT05693766
Recruiting
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Invasive Mammary Carcinoma, Metastatic Breast Cancer
Register for Updates
Customized TULSA-PRO Ablation Registry
NCT05001477
Recruiting
This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a patient's quality of life is affected throughout their follow-up and lifetime.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Register for Updates
EGCG for Hepatocellular Carcinoma Chemoprevention
NCT06015022
Recruiting
This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: UT Southwestern, Dallas, Texas
Conditions: Cirrhosis, Liver
Register for Updates
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT06332092
Recruiting
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Exploration of Central Venous Catheter Protective Devices in the Pediatric Population: A Mixed Methods Study
NCT05415449
Recruiting
1. to determine the feasibility of utilizing a wearable device 2. to prospectively measure and evaluate parent and nurse satisfaction with the protective wearable device. This is a sequential, convergent mixed methods study design in which qualitative interview data will be collected first followed by quantitative data. Scheme and Outcomes: Identify eligible patients--Informed Consent--Provide education and two protective wearable device--Demographic data (electronic health record)--Interview... Read More
Gender:
ALL
Ages:
Between 0 years and 12 years
Trial Updated:
11/04/2024
Locations: Children's Health, Dallas, Texas
Conditions: Central Line
Register for Updates
MASA Valve Early Feasibility Study
NCT05452720
Recruiting
The MASA Valve Early Feasibility Study (MVEFS) multi-site interventional clinical trial within the United States of America with each center following a common protocol.The objective of the trial is to evaluate the safety and probable benefit of MASA Valve in the indicated subset of patients requiring Right Ventricular Outflow Tract Reconstruction (RVOTR). As an early feasibility study, the purpose is determine the feasibility of success of the device in order to gather early data towards a futu... Read More
Gender:
ALL
Ages:
Between 0 years and 22 years
Trial Updated:
11/04/2024
Locations: Childrens Medical Center Dallas, Dallas, Texas
Conditions: Tetrology of Fallot, Pulmonary Stenosis, Truncus Arteriosus, Transposition of Great Vessels, Pulmonary Atresia, Ross Procedure
Register for Updates